This station earns commissions on purchases made through the link(s) on this page. TL;DR: Get the latest Microsoft Project Professional 2024 for a one-time payment of $39.97 and take full control of ...

Lucid-MS, an experimental drug for multiple sclerosis, targets myelin loss. Developer Quantum Biopharma has now completed two FDA-requested toxicology studies testing the oral therapy. The results are ...

Jacob Soboroff arrived at MSNBC a decade ago with limited experience in television news. Fresh off stints at YouTube and AMC, he joined the cable network as it was pivoting away from an opinionated ...

MEMPHIS, Tenn. — Two women are among four DeSoto County residents indicted by a Grand Jury for allegedly defrauding the State of Mississippi out of more than $96,993.40 in public assistance funds ...

There has been a lot of chatter surrounding Project B, which is a new global women's basketball league that's set to launch in the fall of 2026. The league is five-on-five, will feature six 11-player ...

Iris Alonzo-Salgado, 24, of Frederick, was found guilty of first-degree murder and gang-related charges. The conviction is tied to the 2023 killing of 18-year-old Rosa Sánchez Merino in Olney.

The Cincinnati Reds had a very mid-year at the plate. Only a few players posted above-average years at the dish, with no one really going off. Noelvi Marte found himself a home in right field and will ...

Alyssa Thomas is the second major signing for the new Project B women's basketball league that will play in the WNBA offseason. Thomas joins Nneka Ogwumike as veteran WNBA All-Stars to sign with the ...

IN SPACE - AUGUST 11: In this handout photo provided by NASA, the Canadarm2 (center) and solar array panel wings on the International Space Station are extended during the mission's first planned ...

WILKES-BARRE — After spending the last six-plus years in the National Hockey League playing the game at its highest level, Ryan Graves finds himself back in the American Hockey League with the ...

Zenas Biopharma’s autoimmune drug candidate has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study. The midstage MoonStone study saw 116 ...